Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $10.03 to $10.64
• 50-Day Range: $9.71 to $23.50
• 52-Week Range: $8.89 to $24.50
• Volume: 175,633 shs
• Average Volume: 503,008 shs
• Market Capitalization: $454.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.83
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the start of the year. Since then, BBNX shares have decreased by 56.0% and is now trading at $10.48.
View the best growth stocks for 2025 here.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) released its earnings results on Tuesday, March, 25th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.42) by $1.40. The business had revenue of $20.44 million for the quarter, compared to analyst estimates of $20.01 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share.

When did the company's quiet period expire?

Beta Bionics' quiet period expired on Tuesday, March 11th. Beta Bionics had issued 12,000,000 shares in its public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Beta Bionics' major shareholders?

Top institutional shareholders of Beta Bionics include Rhumbline Advisers (0.03%). Insiders that own company stock include Hadley Harbor Aggre Wellington and Mike Mensinger.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/25/2025
• Today: 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.83
• High Stock Price Target: $30.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +137.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 6.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,349,000
• Free Float: N/A
• Market Cap: $454.30 million
• Optionable: N/A
• Beta: N/A